AAAAAA

   
Results: 1-7 |
Results: 7
Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model
Authors: Lambright, ES Kang, EH Force, S Lanuti, M Caparrelli, D Kaiser, LR Albelda, SM Molnar-Kimber, KL
Citation: Es. Lambright et al., Effect of preexisting anti-herpes immunity on the efficacy of herpes simplex viral therapy in a murine intraperitoneal tumor model, MOL THER, 2(4), 2000, pp. 387-393
Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer
Authors: Coukos, G Makrigiannakis, A Kang, EH Rubin, SC Albelda, SM Molnar-Kimber, KL
Citation: G. Coukos et al., Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer, CLIN CANC R, 6(8), 2000, pp. 3342-3353
Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy
Authors: Coukos, G Makrigiannakis, A Montas, S Kaiser, LR Toyozumi, T Benjamin, I Albelda, SM Rubin, SC Molnar-Kimber, KL
Citation: G. Coukos et al., Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy, CANC GENE T, 7(2), 2000, pp. 275-283
Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections
Authors: Zhou, TL Guo, JT Nunes, FA Molnar-Kimber, KL Wilson, JM Aldrich, CE Saputelli, J Litwin, S Condreay, LD Seeger, C Mason, WS
Citation: Tl. Zhou et al., Combination therapy with lamivudine and adenovirus causes transient suppression of chronic woodchuck hepatitis virus infections, J VIROLOGY, 74(24), 2000, pp. 11754-11763
Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer
Authors: Coukos, G Makrigiannakis, A Kang, EH Caparelli, D Benjamin, I Kaiser, LR Rubin, SC Albelda, SM Molnar-Kimber, KL
Citation: G. Coukos et al., Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer, CLIN CANC R, 5(6), 1999, pp. 1523-1537
Combined therapy with chemotherapeutic agents and herpes simplex virus type IICP34.5 mutant (HSV-1716) in human non-small cell lung cancer
Authors: Toyoizumi, T Mick, R Abbas, AE Kang, EH Kaiser, LR Molnar-Kimber, KL
Citation: T. Toyoizumi et al., Combined therapy with chemotherapeutic agents and herpes simplex virus type IICP34.5 mutant (HSV-1716) in human non-small cell lung cancer, HUM GENE TH, 10(18), 1999, pp. 3013-3029
Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system
Authors: Lambright, ES Caparrelli, DJ Abbas, AE Toyoizumi, T Coukos, G Molnar-Kimber, KL Kaiser, LR
Citation: Es. Lambright et al., Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system, ANN THORAC, 68(5), 1999, pp. 1756-1761
Risultati: 1-7 |